News | December 18, 2025
Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year
This recognition demonstrate excellence in intellectual property (IP) value creation.
This recognition demonstrate excellence in intellectual property (IP) value creation.
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Expands bioprocessing footprint across Asia
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Growing patent filings and tier-2 innovators reflect expanding national research base
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Subscribe To Our Newsletter & Stay Updated
